Q-omics provides the consensus-scored HAVCR2 profile across patient tissues and cancer cell-line models. HAVCR2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HAVCR2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HAVCR2 RNA expression shows 22,102 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, HNSC, and LSCC as cancer lineages where HAVCR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HAVCR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HAVCR2 survival associations across molecular data types. HAVCR2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HAVCR2 RNA expression–survival associations across cancer types. High HAVCR2 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, KIRC, CESC and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HAVCR2 RNA expression.
This table summarizes HAVCR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HAVCR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HAVCR2 shows lower tumor expression in LUAD and LUSC and higher tumor expression in HNSC, KIRC, THCA and STAD. The HNSC box plot shows higher HAVCR2 RNA expression in tumor versus normal tissue (log2 FC = +1.267, t-test p < 0.001).
This table shows molecular features associated with HAVCR2 in patient tissues and cancer cell lines. In patient samples, HAVCR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HAVCR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and UPPER_AERODIGESTIVE_TRACT.
